A new analysis of data from a nationwide hospital-based dataset shows that black women have higher odds of being diagnosed with triple-negative breast cancer-a subtype associated with poorer prognosis-than do white women, regardless of socioeconomic status (SES). The report was published in the June issue of Breast Cancer Research and Treatment.
A new analysis of data from a nationwide hospital-based dataset shows that black women have higher odds of being diagnosed with triple-negative breast cancer-a subtype associated with poorer prognosis-than do white women, regardless of socioeconomic status (SES). The report was published in the June issue of Breast Cancer Research and Treatment.
The goal of the study, by researchers from the American Cancer Society, was to estimate the odds of breast cancer subtypes in minorities versus non-Hispanic whites stratified by SES. The authors used the National Cancer Data Base to identify breast cancer cases diagnosed in 2010 and 2011, the only 2 years since US cancer registries began collecting HER2 results. Breast cancer cases were classified into five subtypes, based on hormone receptor (HR) and HER2 status: HR+/HER2-, HR+/HER2+, HR-/HER2+ (HER2-overexpressing), HR-/HER2- (TN), and unknown.
Odds ratios (ORs) for non-HR+/HER2-subtypes to HR+/HER2- for racial/ethnic groups were estimated using polytomous logistic regression. A composite of insurance status and areal-level incomes were used to control for and stratify by SES.
Non-Hispanic black and Hispanics were 84% (OR=1.84; 95% CI 1.77-1.92) and 17% (OR=1.17; 95% CI 1.11-1.24) more likely than white women to have TN subtypes of breast cancer versus HR+/HER2-, respectively. Odds of being diagnosed with HER2-overexpressing subtype versus HR+/HER2- were 1.45 times greater in Asian/Pacific Islanders than in non-Hispanic white women (OR=1.45; 95% CI 1.31-1.61). The researchers found similar ORs for race in high and low strata of SES.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More